Objective This study aims to compare the development situation and regulatory focus of the health science and technology policy between China and the United States,and put forward suggestions for improving the health science and technology policy system in China.Methods The health science and technology policies of China and the United States were systematically sorted out,and quantitative analysis and comparative analysis were conducted from the aspects of time distribu-tion,policy issuing authority,policy type,and regulation field.Results(1)In terms of the quantity of health science and technology policies,China deployed 76 related policies from 2002 to 2023,and the annual number of policies increased from 1 in 2002 to 11 in 2016 and 10 in 2022.The United States deployed 110 related policies from 2002 to 2023,and the annual number of policies increased from 2 in 2002 to 13 in 2023.(2)In terms of the policy issuing authorities,China's National Health Com-mission accounted for 57％of policy issuance,while the NIH and HHS accounted for 62％and 20％respectively.(3)In terms of policy types,strategic planning and implementation policies account for 41％and 51％of China's health science and technol-ogy policies,respectively,compared with 13％and 81％in the United States.(3)In terms of regulatory domains,China's health science and technology policies mainly focus on macro-planning,biosafety,new technology supervision,clinical re-search,and industrial innovation,accounting for 36％,18％,11％,10％,and 8％of the total,respectively.The health sci-ence and technology policies in the United States were mainly distributed in clinical research,biosafety,animal ethics,scientific data,and research integrity,accounting for 15％,12％,11％,11％,and 11％of the total,respectively.Conclusions(1)The deployment of health science and technology policies in China and the United States is accelerating.However,China has fewer overall health science and technology policies and should strengthen its policy deployment.(2)Health administration depart-ments are important entities in deploying health science and technology policies.They will remain the mainstream in the next phase of health science and technology policy deployment in the health sector.(3)Compared with the pyramid distribution of health science and technology policies in the United States,the proportion of implementation policies in China is relatively low,which is not conducive to implementation and should further increase the deployment of implementation policies(4)Regarding regulatory domains,China has an overemphasis on macro-planning policies while lacking sufficient policy deployment in areas such as clinical research,scientific data,and animal ethics.In the future,policy deployment should be strengthened in areas such as clinical research and scienific data.
HealthScience and technology policyComparative research
维普
万方数据
